Skip to content
MarketScale
‹ Back to Industries

Sciences

The Life of a Scope

Sam Harrison, a Senior Clinical Educator at Censis Technologies, discussed the lifecycle of a scope and how Censis's tools, ScopeTrac and CensiTrac, are essential. The tools aid in the deamination, cleaning, disinfecting, and storage tracking processes, and ensure compliance with regulations.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Censis on MarketScale.

By Sciences · CensitracEndoscope ReprocessorScope TechnologyScopes
Share

Key takeaways

01

Scopes go through deamination before entering the OR.

02

CensiTrac tracks and documents cleaning and reprocessing procedures.

03

ScopeTrac helps comply with regulatory requirements and enhance tracking capabilities.

Sam Harrison, Senior Clinical Educator at Censis Technologies, provided Tyler Kern with an education in endoscopy when he guided him through the lifecycle of a scope and how Censis technologies’ ScopeTrac and CensiTrac play a vital role in the process.

Scopes first go through a deamination process before they enter the OR. CensiTrac then captures the cleaning and reprocessing procedures.

“When the tech checks that scope into the scope processing module, the instructions for use are displayed,” Harrison said. “Those instructions for use can be customized per the scope model, the manufacturer’s IFUs can be uploaded, or video can be uploaded to make it as easy as possible for the end-user.”

After the scope receives reprocessing, it goes to a cleaning room for disinfecting. This process requires tracking, which CensiTrac streamlines. Once disinfected and logged, a scope will go to a clean storage area, and CensiTrac will provide information on those scope’s storage location.

Once a scope enters the procedure room, CensiTrac’s case-tracking module can associate that scope to a patient through a case ID#. “In each area, CensiTrac is used to track and document every required process,” Harrison said.

ScopeTrac is another critical piece of the digital scope record process that makes it easy to comply with regulations.

“Having those processing steps there to help abide by the regulatory requirements is huge,” Harrison said. And, with the added functionality of video and image uploads, techs have additional tools and resources at their disposal to correctly identify and log in scopes.

While ScopeTrac with CensiTrac addresses all these needs, Harrison mentioned that there is now ScopeTrac Advanced, which provides additional solutions, such as OR scheduler interface capabilities.

Interested in learning more about Censis Technologies’ surgical asset management platform? Visit Censis.com.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Censis

Part of this channel

Censis

Surgical instrument management software for over 1,300 U.S. hospitals.

Visit the channel →

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

Senior Clinical Educator at Censis Technologies

Sam Harrison guides the education in endoscopy and the lifecycle of scopes at Censis Technologies. He explains how ScopeTrac and CensiTrac play vital roles in the process. He ensures compliance with regulatory requirements and streamlines the processes from cleaning to patient tracking.